PYPD earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -2.09. Updated 2026-07-23.
PolyPid (PYPD) Research Hub
PolyPid (PYPD) trades on NASDAQ, IL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 5.15 USD (-0.96%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.09, market cap 0.04B. This hub links to the full technical, earnings and options research available for PYPD.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IL |
| Last close | 5.15 USD (-0.96%) |
| 52-week range | 3.65 USD – 5.62 USD |
| Trend regime | Range |
| 14-day RSI | 62.6 (Bullish) |
| Trailing P/E | -2.09 |
| Market cap | 0.04B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for PYPD
Covered Call on PYPD: how it works, illustrative setup around the real 5.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PYPD: how it works, illustrative setup around the real 5.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PYPD: how it works, illustrative setup around the real 5.15 USD price, max profit/loss, breakeven and when to use it. Educational.
PYPD technical analysis: range, last 5.15 USD, RSI 62.6, 52w range 3.65 USD–5.62 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PYPD in?
PolyPid (PYPD) is classified under Healthcare (Biotechnology), listed on NASDAQ, IL.
Is PYPD in an uptrend or downtrend?
As of 2026-09-11, PYPD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PYPD's trailing P/E ratio?
PYPD's trailing P/E is -2.09, with a market cap of 0.04B. See the earnings research page for full valuation detail.
When does PYPD next report earnings?
PYPD is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.365 USD.